Swiss National Bank recently reduced its holding in Rhythm Pharmaceuticals by a modest 900 shares during the first quarter, as disclosed in a new SEC filing. Despite the small adjustment, the bank retains a significant position in the company.

PNC Financial Services Group has quietly pared back its stake in Vericel Corporation. A recent SEC filing shows the bank sold 378 shares in the first quarter—an 8.2 percent trim that leaves it holding 4,251 shares of the NASDAQ-listed biotech firm.

Zacks Small Cap has inched its third-quarter 2025 earnings forecast for Longeveron Inc. higher, trimming the biotech’s expected loss to 26 cents a share. The research note, issued Aug. 14 by analyst B. Sorensen, offers a modest but notable vote of confidence in the Nasdaq-listed company.